Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance, with raised guidance and record high revenues. Product development shows momentum with potential blockbuster drugs and a robust pipeline. Market strategy is solid with royalty revenue growth and strategic investments. Financial health is stable with manageable expenses and significant cash reserves. Shareholder returns are likely supported by positive financial outcomes. Q&A insights reinforce optimistic guidance and strategic focus. Given the market cap, the stock price is expected to react positively, likely increasing by 2% to 8% over the next two weeks.
Key Financial Performance
Full-year adjusted EPS Exceeded original 2025 guidance by more than 30%, reflecting strategic changes, lean operating structure, focused investment strategy, and strong royalty portfolio.
Full-year royalty revenue Grew 48% year-over-year, driven by FILSPARI ramp, launches of Merck's Ohtuvayre and CAPVAXIVE, ZELSUVMI commercial launch, and Recordati Qarziba growth.
Core revenue Increased from $108 million in 2022 to $240 million in 2025, reflecting meaningful growth.
Total GAAP revenue $268 million in 2025, up from $167 million in 2024, including a gain from the Pelthos business sale. Excluding the gain, core revenue grew 43% year-over-year.
Royalty revenue $161 million in 2025, a 48% increase year-over-year, driven by FILSPARI, Ohtuvayre, CAPVAXIVE, and Qarziba.
Core adjusted diluted EPS $8.13 in 2025, up 42% year-over-year, driven by higher royalty contributions and operating leverage.
Q4 total revenue $59.7 million, a 39% increase year-over-year, with royalty revenue as the primary growth driver.
Q4 royalty revenue $50.5 million, up 45% year-over-year, driven by FILSPARI, Ohtuvayre, CAPVAXIVE, and Qarziba.
FILSPARI U.S. net sales $103 million in Q4, representing 108% year-over-year growth, with $322 million in net sales for the full fiscal year.
Merck's Ohtuvayre net sales $178 million in Q4 (partial quarter), with $506 million in U.S. net sales for the full year 2025.
Merck's CAPVAXIVE net sales $279 million in Q4 and $755 million for the full year 2025, nearing blockbuster status.
Recordati's Qarziba net sales EUR 159 million for the full year 2025, representing 12% growth.
Adjusted net income for Q4 $42.7 million or $2.02 per diluted share, compared to $1.27 in the prior year, driven by higher royalty revenue.
R&D expense for Q4 $3.5 million, down from $4.4 million in the prior year.
G&A expense for Q4 $25 million, relatively flat year-over-year.
Full-year R&D expense $81.2 million in 2025, up from $21.4 million in 2024, including $62 million related to Castle Creek and Orchestra investments.
Full-year G&A expense $92.4 million in 2025, up from $78.7 million in 2024, driven by stock-based compensation, Pelthos transaction costs, and headcount-related costs.
Cash, cash equivalents, and short-term investments $734 million at the end of 2025, with over $1 billion in deployable capital including equity holdings and credit facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FILSPARI: Continued ramp in sales, contributing to 48% growth in royalty revenue. U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year.
Merck's Ohtuvayre: Successful launch with $178 million in Q4 net sales and $506 million for the full year 2025. Tracking as the strongest launch in COPD history.
CAPVAXIVE: Reported $279 million in Q4 net sales and $755 million for the full year, nearing blockbuster status.
ZELSUVMI: Rescued from bankruptcy, achieved FDA approval, and launched commercially to address molluscum contagiosum.
QTORIN rapamycin: Positive Phase 3 trial results for microcystic lymphatic malformations (mLM), likely to become the first FDA-approved therapy for this rare disease.
Royalty financing: Demand for royalty capital has doubled over the last 5 years, with Ligand positioned uniquely in the expanding biopharmaceutical royalty financing sector.
Geographic expansion: Ohtuvayre's NDA accepted in China for COPD treatment, indicating potential for significant upside from geographic expansion.
Portfolio management strategy: Launched a systematic approach to track progress, increase partner dialogue, and identify new investment opportunities.
Financial performance: 2025 core revenue grew 43% year-over-year to $240 million, with adjusted EPS increasing 42% to $8.13 per share.
Capital base: Ended 2025 with over $1 billion in deployable capital, including $734 million in cash and investments.
Special situations transaction: Executed a strategic merger and financing of Pelthos and Channel Therapeutics, creating significant equity and royalty value.
Lasofoxifene: Reassigned license to LeonaBio, supported by $90 million PIPE financing, with potential peak sales of $1 billion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Delays: The FDA extended the review timeline for the sNDA for FILSPARI in FSGS, which could delay its market entry and impact revenue projections.
Financial Challenges in Partnerships: Sermonix Pharmaceuticals faced financial difficulties during the pivotal study of lasofoxifene, requiring Ligand to intervene and reassign the license to LeonaBio.
Supply Chain and Commercialization Risks: The success of commercial launches like Ohtuvayre and FILSPARI depends on effective supply chain management and market penetration, which could face disruptions or challenges.
R&D and Operational Costs: Full-year R&D expenses increased significantly to $81.2 million, driven by accounting treatments and scaling efforts, which could pressure margins if not managed effectively.
Market Competition: Products like Ohtuvayre and CAPVAXIVE face competitive pressures in their respective markets, which could impact sales growth and royalty revenues.
Economic and Funding Environment: The biopharmaceutical funding environment remains challenging, although Ligand has positioned itself well with royalty financing. Any adverse changes in this environment could impact future investments.
Geographic Expansion Risks: The success of products like Ohtuvayre in new markets such as China is uncertain and could face regulatory or market entry challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Ligand expects total revenue of $245 million to $285 million for 2026, with royalty revenue projected at $200 million to $225 million, representing 32% growth at the midpoint. By 2030, the company anticipates more than $430 million in revenue.
Earnings Projections: Adjusted EPS for 2026 is expected to be approximately $8 to $9 per share. By 2030, adjusted EPS is projected to exceed $13.50 per share.
Royalty Growth: Ligand expects a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by commercial programs, development stage programs, and future investments.
Product-Specific Projections: FILSPARI, Ohtuvayre, CAPVAXIVE, and ZELSUVMI are expected to drive royalty growth in 2026. FILSPARI is projected to have significant commercial upside if approved in Japan. Ohtuvayre is tracking ahead of expectations and has potential for geographic expansion.
Pipeline Developments: Palvella plans to submit an NDA for QTORIN rapamycin for mLM in the second half of 2026, with potential U.S. commercial opportunity of $1 billion to $3 billion annually. Lasofoxifene is expected to have top-line data readout in mid-2027, with potential peak annual royalties of $80 million.
Market Trends: The royalty funding market has doubled over the last 5 years, and Ligand sees growth in demand for royalty capital. Royalty financing is becoming a strategic capital structure tool for biopharmaceutical companies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What clinical updates can be expected for the late-stage royalty portfolio in 2026?
A:The late-stage pipeline is active with updates expected for Qarziba (U.S. approval and Ewing sarcoma studies), BOT/BAL (Phase 3), AVIM therapy and Virtue-SAB trials (Phase 3), Castle Creek's DEB treatment (Phase 3), QTORIN rapamycin for cutaneous venous malformations, lasofoxifene, and Tzield for type 1 diabetes. Additional late-stage assets will be added to the pipeline.
Q:What is the progress on monetizing older assets in the portfolio?
A:There are 5 to 10 active opportunities and another 10 planned engagements over the next few quarters. Some involve new investments, while others leverage the team's expertise in regulatory and commercial domains. An example is lasofoxifene, which has added value to the portfolio.
Q:What is the larger opportunity for Tzield, and what is its potential peak sales size?
A:Tzield is a potentially blockbuster opportunity for Sanofi, targeting Stage 2 type 1 diabetes (presymptomatic patients) and Stage 3 (newly diagnosed symptomatic patients). Stage 3 is commercially larger due to easier patient access. Sanofi is building the market, and a decision on Stage 3 is expected in the first half of the year.
Q:How does the reiterated guidance range account for the delay in FSGS approval?
A:The guidance assumes a modest, risk-adjusted $4 million contribution from FSGS royalties in 2026. The delay minimally impacts this figure, and FSGS is expected to be a minor contributor in 2026 but more significant in later years.
Q:Are there any updates to the selection criteria for potential partnerships?
A:The focus remains on high clinical value assets, with deal sizes in the $30 million to $80 million range. The strategy may involve slightly larger deals and more deals over time to generate greater value.
Q:What differentiates Castle Creek's D-Fi from Krystal's VYJUVEK?
A:D-Fi is an injectable treatment for DEB, expanding body surface area coverage compared to VYJUVEK's topical application. It addresses chronic wounds and may be used for hands and feet in the future. VYJUVEK validated the market with $400 million in 2025 sales, and D-Fi could complement it.
Q:Does the delay in FSGS approval impact the 2026 outlook for FILSPARI?
A:The delay has negligible impact. The 2026 guidance assumes a $4 million contribution from FSGS, which is minor.
Q:What is the potential market size for FILSPARI in FSGS and IgAN, and what are the opportunities outside the U.S.?
A:Consensus estimates for FILSPARI are $1 billion per indication (FSGS and IgAN), with a 9% royalty to Ligand (~$90 million per indication). FSGS may launch faster due to lack of treatment options. IgAN is prevalent in Japan, offering a sizable opportunity, though specific expectations are not disclosed.
Q:Is Jazz's Rylaze a key royalty driver, and what is its outlook?
A:Rylaze is a mature product and a key royalty revenue driver. It continues to perform strongly, but no near-term catalysts are expected to significantly drive sales growth.
Q:What is the strategy for equity holdings like Pelthos?
A:The strategy is long-term, with no immediate plans for liquidity. Equity holdings are seen as a source of cash when mature, but there is significant upside potential.
Q:How is the current market environment affecting opportunities?
A:The market is better than two years ago, with royalty financing growing rapidly. It is now a mainstream part of capital structures, offering long-term investments tied to asset life cycles. The pipeline of opportunities is robust, and the team is focused on high-probability, high-return deals.
Q:Review of Unclear Management Responses
A:No questions were identified where management avoided giving a direct answer or lacked clarity in their responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BAL Agenus
BOT BAL
China
FILSPARI sale
Fast Track
Merck Ohtuvayre
NDA
Ohtuvayre CAPVAXIVE
PIPE
Pfizer
Phase result
Phase trial
RD expense
Sanofi
Stage disease
Track designation
Tzield
angiokeratomas
breakthrough therapy
cVM
catalyst
depth
disease patient
indication
lasofoxifene
license
mLM
partnership
rapamycin treatment
royalty financing
strength
treatment patient
LGND Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript
Positive5-9
The earnings call highlights strong financial health with nearly $1 billion in available capital, an optimistic outlook on revenue and EPS growth, and strategic acquisitions like XOMA expected to drive synergies and EPS accretion. Despite a GAAP EPS loss, the adjusted metrics and guidance remain robust, with promising pipeline developments and a stable royalty growth trajectory. The Q&A session reinforced confidence in sustained growth without the need for additional deals, and management's clear responses indicate a well-managed strategy. Considering the small-cap nature of the stock, a positive reaction is likely.
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call indicates strong financial performance, with raised guidance and record high revenues. Product development shows momentum with potential blockbuster drugs and a robust pipeline. Market strategy is solid with royalty revenue growth and strategic investments. Financial health is stable with manageable expenses and significant cash reserves. Shareholder returns are likely supported by positive financial outcomes. Q&A insights reinforce optimistic guidance and strategic focus. Given the market cap, the stock price is expected to react positively, likely increasing by 2% to 8% over the next two weeks.
Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call summary highlights strong financial performance with significant revenue and EPS growth, positive product launches, and raised guidance. The Q&A session reveals management's focus on strategic investments and alignment with FDA initiatives, which are viewed positively by analysts. Despite competitive risks, the company's cash position and strategic investments provide a solid foundation. The raised guidance and strong product performance contribute to a positive outlook, suggesting a stock price increase of 2% to 8% over the next two weeks.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlights strong financial performance with improved GAAP and non-GAAP net income. Management's optimistic outlook on product launches and strategic partnerships, like with Merck, along with robust M&A opportunities, indicate strong growth potential. Although there are concerns about operating expenses and tax rates, the overall sentiment is positive, especially with expected revenue growth and strategic investments. The market cap suggests moderate reaction, leading to a positive stock price movement prediction.
LGND Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
